The 37th Annual Transcatheter Cardiovascular Therapeutics (TCT2025) symposium was held grandly in San Francisco, USA, ...
Alixorexton, an investigational, oral, selective orexin 2 receptor agonist, demonstrated meaningful improvements across the trial’s dual primary endpoints of change from baseline in Maintenance of ...
News Medical on MSN
Diabetes drugs semaglutide and tirzepatide show real-world heart benefits
In a large real-world analysis across three U.S. healthcare databases, semaglutide and tirzepatide showed cardiovascular benefits consistent with randomized trials. Semaglutide lowered heart attack ...
Adolescents treated with doxycycline were up to one third less likely to develop schizophrenia as adults, a Finnish study ...
EssilorLuxottica expands its myopia management platform with Essilor Stellest 2.0 lenses, smart glasses and an innovative pre-myopia solution ...
Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 - - Reported highly positive 12-week primary endpoint results from Phase ...
BACKGROUND: Current guidelines recommend a stepwise strategy to achieve low-density lipoprotein cholesterol (LDL-C) goals after acute coronary syndrome (ACS). Earlier intensive strategies based on a ...
Learn five key signs your baby needs a nasal aspirator and when to seek medical help for congestion. Expert baby care ...
2don MSN
First-in-human trial of CRISPR gene-editing therapy safely lowers cholesterol and triglycerides
In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback